|Systematic (IUPAC) name|
|Trade names||Catena, Raxone, Sovrima|
|Bioavailability||<1% (high first pass effect)|
|Excretion||Urine (80%) and feces|
|Mol. mass||338.439 g/mol|
|(what is this?)|
Idebenone (pronounced eye-deb-eh-known, trade names Catena, Raxone, Sovrima, among others) is a drug that was initially developed by Takeda Pharmaceutical Company for the treatment of Alzheimer's disease and other cognitive defects. This has been met with limited success. The Swiss company Santhera Pharmaceuticals has started to investigate it for the treatment of neuromuscular diseases. In 2010, early clinical trials for the treatment of Friedreich's ataxia and Duchenne muscular dystrophy have been completed. As of December 2013[update] the drug is not approved for these indications in North America or Europe.
- 1 Uses
- 1.1 Indications that are or were approved in some territories
- 1.2 Indications being explored
- 1.3 Life style
- 2 Pharmacology
- 3 References
Indications that are or were approved in some territories
Nootropic effects and Alzheimer's disease
Idebenone improved learning and memory in experiments with mice. In humans, evaluation of Surrogate endpoints like electroretinography, auditory evoked potentials and visual analogue scales also suggested positive nootropic effects, but larger studies with hard endpoints are missing.
Research on idebenone as a potential therapy of Alzheimer's disease have been inconsistent, but there may be a trend for a slight benefit. In May 1998, the approval for this indication was cancelled in Japan due to the lack of proven effects. In some European countries, the drug is available for the treatment of individual patients in special cases.
Friedreich's ataxia (Sovrima)
Preliminary testing has been done in humans and found idebenone to be a safe treatment for Friedreich's ataxia (FA), exhibiting a positive effect on cardiac hypertrophy and neurological function. The latter was only significantly improved in young patients. In a different experiment, a one-year test on eight patients, idebenone reduced the rate of deterioration of cardiac function, but without halting the progression of ataxia.
The drug was approved for FA in Canada in 2008 under conditions including proof of efficacy in further clinical trials. However on February 27, 2013, Health Canada announced that idebenone would be voluntarily recalled as of April 30, 2013 by its Canadian manufacturer, Santhera Pharmaceuticals, due to the failure of the drug to show efficacy in the further clinical trials that were conducted. In 2008, the European Medicines Agency (EMA) refused a marketing authorisation for this indication. As of 2013 the drug was not approved for FA in Europe nor in the US, where there is no approved treatment.
Indications being explored
Duchenne muscular dystrophy (Catena)
Leber's hereditary optic neuropathy (Raxone)
Leber's hereditary optic neuropathy (LHON) is a mitochondrially inherited (mother to all offspring) degeneration of retinal ganglion cells (RGCs) and their axons that leads to an acute or subacute loss of central vision; this affects predominantly young adult males. Santhera completed a Phase III clinical trial in this indication in Europe with positive results, and submitted an application to market the drug to European regulators in July 2011. In January 2013, the request for marketing authorisation was refused by the EMA.
Other neuromuscular diseases
Phase I and II clinical trials for the treatment of MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) and primary progressive multiple sclerosis are ongoing as of December 2013[update].
Idebenone is claimed to have properties similar to CoQ10 in its antioxidant properties, and has therefore been used in anti-aging on the basis of free-radical theory. Clinical evidence for this use is missing. It has been used in topical applications to treat wrinkles.
In cellular and tissue models, idebenone acts as a transporter in the electron transport chain of mitochondria and thus increases the production of adenosine triphosphate (ATP) which is the main energy source for cells, and also inhibits lipoperoxide formation. Positive effects on the energy household of mitochondria has also been observed in animal models. Clinical relevance of these findings has not been established.
Idebenone is well absorbed from the gut but undergoes excessive first pass metabolism in the liver, so that less than 1% reach the circulation. This rate can be improved with special formulations (suspensions) of idebenone and by administering it together with fat food; but even taking these measures bioavailability still seems to be considerably less than 14% in humans. More than 99% of the circulating drug are bound to plasma proteins. Idebenone metabolites include glucuronides and sulfates, which are mainly (~80%) excreted via the urine.
- "CHMP Assessment Report for Sovrima". European Medicines Agency. 20 November 2008. pp. 6, 9–11, 67f.
- ClinicalTrials.gov NCT00229632 Idebenone to Treat Friedreich's Ataxia
- ClinicalTrials.gov NCT00654784 Efficacy and Tolerability of Idebenone in Boys With Cardiac Dysfunction Associated With Duchenne Muscular Dystrophy (DELPHI)
- Liu, XJ; Wu, WT (1999). "Effects of ligustrazine, tanshinone II A, ubiquinone, and idebenone on mouse water maze performance.". Zhongguo yao li xue bao = Acta pharmacologica Sinica 20 (11): 987–90. PMID 11270979.
- Schaffler, K; Hadler, D; Stark, M (1998). "Dose-effect relationship of idebenone in an experimental cerebral deficit model. Pilot study in healthy young volunteers with piracetam as reference drug.". Arzneimittel-Forschung 48 (7): 720–6. PMID 9706371.
- Gutzmann, H; Kühl, KP; Hadler, D; Rapp, MA (2002). "Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study.". Pharmacopsychiatry 35 (1): 12–8. doi:10.1055/s-2002-19833. PMID 11819153.
- Parnetti, L; Senin, U; Mecocci, P (1997). "Cognitive enhancement therapy for Alzheimer's disease. The way forward.". Drugs 53 (5): 752–68. doi:10.2165/00003495-199753050-00003. PMID 9129864.
- Di Prospero NA, Baker A, Jeffries N, Fischbeck KH (October 2007). "Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial". Lancet Neurol 6 (10): 878–86. doi:10.1016/S1474-4422(07)70220-X. PMID 17826341.
- Tonon C, Lodi R (September 2008). "Idebenone in Friedreich's ataxia". Expert Opin Pharmacother 9 (13): 2327–37. doi:10.1517/14656522.214.171.1247. PMID 18710357.
- Buyse G, Mertens L, Di Salvo G, et al. (May 2003). "Idebenone treatment in Friedreich's ataxia: neurological, cardiac, and biochemical monitoring". Neurology 60 (10): 1679–81. doi:10.1212/01.wnl.0000068549.52812.0f. PMID 12771265.
- Heath Canada Fact Sheet - Catena
- Voluntary Withdrawal of Catena from the Canadian Market
- Margaret Wahl for Quest Magazine, MAY 28, 2010. FA Research: Idebenone Strikes Out Again
- NINDS Fact Sheet
- Buyse, GM; Van Der Mieren, G; Erb, M; D'hooge, J; Herijgers, P; Verbeken, E; Jara, A; Van Den Bergh, A et al. (2009). "Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance". European Heart Journal 30 (1): 116–24. doi:10.1093/eurheartj/ehn406. PMC 2639086. PMID 18784063.
- ClinicalTrials.gov NCT01027884 Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD) (DELOS)
- Klopstock T, et al (2011) A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy. Brain.134(Pt 9):2677-86.
- Staff, European Biotechnology News, July 26, 2011. Santhera publishes pivotal trial results of idebenone and goes for EU approval
- "Refusal of the marketing authorisation for Raxone (idebenone)". European Medicines Agency. 17 January 2013.
- ClinicalTrials.gov NCT00887562 Study of Idebenone in the Treatment of Mitochondrial Encephalopathy Lactic Acidosis & Stroke-like Episodes (MELAS)
- ClinicalTrials.gov NCT00950248 Double Blind Placebo-Controlled Phase I/II Clinical Trial of Idebenone in Patients With Primary Progressive Multiple Sclerosis (IPPoMS)
- McDaniel D, Neudecker B, Dinardo J, Lewis J, Maibach H (September 2005). "Clinical efficacy assessment in photodamaged skin of 0.5% and 1.0% idebenone". J Cosmet Dermatol 4 (3): 167–73. doi:10.1111/j.1473-2165.2005.00305.x. PMID 17129261.
- Suno M, Nagaoka A (May 1988). "[Effect of idebenone and various nootropic drugs on lipid peroxidation in rat brain homogenate in the presence of succinate]". Nippon Yakurigaku Zasshi (in Japanese) 91 (5): 295–9. doi:10.1254/fpj.91.295. PMID 3410376.